Carbohydrate-Based Antibacterial Vaccines: Current Progress and Future Outlook

Shivatare, Sachin S.; Wu, Chung‐Yi; Wu, Corinna

doi:10.1142/9781783267200_0013

Cited by 1 publication

(2 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first generation of Hib vaccines, made with purified polyribosyl-ribitol phosphate, induced relatively low titers of serum antibodies, insufficient to protect children from invasive disease [ 60 ], and were replaced by Hib PS-conjugate vaccines (PedVaxHIB ® , ActHib ® , HibTiter ® ) [ 61 ]. Vérez Bencomo et al developed the first synthetic glycoconjugate vaccine in 2004 [ 9 ], QuimiHib ® (compound 70 , Figure 8 ) using a one-pot polycondensation strategy starting from synthetic β- d -ribose-(1,1)- d -ribitol-5-H-phosphonate derivative 71 and the phosphodiester-linked compound 72 [ 9 ].…”

Section: Haemophilus Influenzae Type B (Hib)mentioning

confidence: 99%

“…Structural modification of this “self” antigen replacing the N -acetyl group of sialic acid units with an N -propanonyl group [ 165 ] induced high levels of bactericidal IgG antibodies without detection of autoantibodies [ 166 ]. However, its development has been suspended due to the poor performance of the vaccine in a limited human trial and to the high perceived risk of autoimmunity [ 61 ]. A new type of group B vaccine, Bexsero ® (GlaxoSmithKline) developed by conjugation of three recombinant surface antigens (PorA, NadA and fHbp) and outer membrane vesicles from group B strain NZ98/254, is now licensed in more than 35 countries worldwide, including the EU, Australia, Brazil, Canada, Chile, Uruguay and the USA [ 167 , 168 , 169 ].…”

Section: Neisseria Meningitidismentioning

confidence: 99%

See 1 more Smart Citation

Recent Advances in the Synthesis of Glycoconjugates for Vaccine Development

2018

View full text Add to dashboard Cite

During the last decade there has been a growing interest in glycoimmunology, a relatively new research field dealing with the specific interactions of carbohydrates with the immune system. Pathogens’ cell surfaces are covered by a thick layer of oligo- and polysaccharides that are crucial virulence factors, as they mediate receptors binding on host cells for initial adhesion and organism invasion. Since in most cases these saccharide structures are uniquely exposed on the pathogen surface, they represent attractive targets for vaccine design. Polysaccharides isolated from cell walls of microorganisms and chemically conjugated to immunogenic proteins have been used as antigens for vaccine development for a range of infectious diseases. However, several challenges are associated with carbohydrate antigens purified from natural sources, such as their difficult characterization and heterogeneous composition. Consequently, glycoconjugates with chemically well-defined structures, that are able to confer highly reproducible biological properties and a better safety profile, are at the forefront of vaccine development. Following on from our previous review on the subject, in the present account we specifically focus on the most recent advances in the synthesis and preliminary immunological evaluation of next generation glycoconjugate vaccines designed to target bacterial and fungal infections that have been reported in the literature since 2011.

show abstract

Section: Haemophilus Influenzae Type B (Hib)mentioning

confidence: 99%